Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Boris Senior is active.

Publication


Featured researches published by Boris Senior.


Annals of Internal Medicine | 1994

Glycogen Storage Disease in Adults

Gregg M. Talente; Rosalind A. Coleman; Craig A. Alter; Lester Baker; Barbara Illingworth Brown; Robert A. Cannon; Yong Tsong Chen; John F. Crigler; P. Ferreira; J.C. Haworth; Gail E. Herman; Robert M. Issenman; James P. Keating; Randy Linde; Thomas F. Roe; Boris Senior; Joseph I. Wolfsdorf

Table 1 The glycogen storage diseases (GSD) include more than ten separate genetic defects that impair glycogen breakdown, primarily in liver or muscle or both. Even the types most frequently encountered (GSD-Ia and GSD-III) are uncommon, each with an incidence of approximately 1 in 100 000 births. Thus, no single institution has followed and reported on a large series of patients. The importance of several major complications was recognized only recently because only single cases were initially reported. Our study represents the largest number of adults with GSD-Ia and GSD-Ib to be included in one investigation and is the first to focus on clinical and social outcomes. Although two groups of investigators recently described the clinical course of patients with GSD in Europe and Israel, most of the patients studied were children [1, 2]. Relatively little information is available about adults with these diseases. We collected information on adults with GSD-Ia, GSD-Ib, and GSD-III in the United States and Canada in order to identify long-term complications that may be amenable to prevention and to determine the effect of the disease on education, employment, and family life. Table 1. SI Units Glycogen Storage Disease Types Ia, Ib, and III Glycogen storage disease type Ia results from deficient glucose-6-phosphatase activity in liver, kidney, and intestine [3]. Glucose-6-phosphatase is a single 35-kd protein [4]. When glucose-6-phosphatase activity is deficient, the liver is unable to hydrolyze glucose from glucose-6-phosphate that has been derived either from the metabolism of stored glycogen or from gluconeogenesis. Patients must depend on dietary carbohydrate to maintain euglycemia; during a fast of more than a few hours, the serum glucose concentration may decrease profoundly, and seizures are common in children. Mental retardation is uncommon, however, because the brain is protected by its ability to metabolize lactate that is present at high concentrations in the serum. Chronic hypoglycemia causes a sustained increase of counter-regulatory hormones, such as cortisol. In childhood, GSD-Ia typically results in poor growth and delayed puberty. Hyperuricemia occurs probably because ATP synthesis from ADP is driven by deamination of the AMP product to inosine that is subsequently metabolized to uric acid. Renal excretion of uric acid may also be decreased because lactate competes for the renal anion transporter. Fatty liver and hyperlipidemia result from the large influx of adipose-derived fatty acids into the liver in response to low insulin and high glucagon and cortisol concentrations. Anemia that is refractory to iron supplementation is believed to occur because of chronic disease. In untreated adults with GSD-Ia, the blood glucose decreases only to about 2.8 mmol/L (50 mg/dL) after an overnight fast. Symptomatic hypoglycemia is uncommon in untreated adults, but increases of counter-regulatory hormones probably persist. Adults with GSD-Ia have a high incidence of hepatic adenomas and focal segmental glomerulosclerosis [3, 5, 6]. The continuing abnormalities in counter-regulatory hormones, together with the hyperuricemia and hyperlipidemia, may be responsible for many of the complications observed in adult patients. Glycogen storage disease type Ib results from a deficiency of the glucose-6-phosphate translocase that transports glucose-6-phosphate into the lumen of the endoplasmic reticulum where it is hydrolyzed by glucose-6-phosphatase [3]. The translocase has not been purified. Without the translocase, glucose-6-phosphate cannot reach the hydrolytic enzyme; thus, patients with GSD-Ib are also unable to maintain euglycemia. The resulting metabolic consequences are identical in both forms of GSD-I. Because patients with GSD-Ib also have neutropenia and recurrent bacterial infections [3, 7], it seems likely that the glucose-6-phosphate translocase plays a role in normal neutrophil function. In GSD-III, glycogen debranching enzyme is deficient [3]. This enzyme is a 165-kd protein that contains two catalytic sites that are required for activity. The enzyme has been cloned and sequenced [8]. Normally, successive glucose residues are released from glycogen by glycogen phosphorylase until the glycogen chains are within four glucose residues of a branch point. The first catalytic activity of the debranching enzyme (oligo-1,4,-1,4-glucantransferase) transfers three of the remaining glucose residues to the terminus of another glucose chain. The second catalytic activity (amylo-1,6-glucosidase) then hydrolyzes the branch-point glucose residue. Three molecular subgroups of GSD-III have been well defined [9]; each is associated with enzyme deficiency in the liver and with childhood hypoglycemia. In adults with GSD-III, hypoglycemia is uncommon. As in GSD-I, poor growth may be prominent, but the growth rate increases before puberty, and adult height is normal [10]. Additionally, increases in transaminase levels provide evidence of hepatocellular damage, and liver biopsies show periportal fibrosis [10], perhaps related to the abnormal short-branched glycogen structure. In patients with subtype GSD-IIIb, enzyme activity and immunoreactive material are absent in liver but are present in muscle; these patients do not have a myopathy. Patients with GSD-IIIa (78% of cases) lack enzyme activity and lack immunoreactive material in liver and muscle. Patients with GSD-IIId (7% of cases) lack only the transferase activity but have normal immunoreactive material in liver and muscle. In patients with GSD-IIIa and IIId, muscle weakness may occur either in childhood or after the third decade. Cardiomyopathy is apparent only after age 30 years [9]. Treatment of Glycogen Storage Disease For only the past 10 to 15 years, children with GSD-Ia and GSD-Ib were treated with either intermittent uncooked cornstarch or a nocturnal glucose infusion given by intragastric tube. When euglycemia is maintained in this manner, growth and pubertal development are normal, and it is hoped that the late complications of GSD-I will be prevented. A high-protein diet was recommended for patients with GSD-III. Diet supplementation can increase the growth rate in children with GSD-III [11], but beneficial results on the myopathy have been less well documented. In this retrospective study of adults with GSD types Ia, Ib, and III, we found, in addition to complications frequently recognized, a high incidence of osteopenia and fractures and of nephrocalcinosis, kidney stones, and pyelonephritis. We describe the long-term outlook for adult patients with GSD who have not had optimal lifelong dietary glucose therapy. Methods Information on patients 18 years of age or older was obtained by contacting specialists in pediatric metabolism, endocrinology, gastroenterology, and genetics throughout the United States and Canada and by advertising through the Association for Glycogen Storage Diseases and The New England Journal of Medicine. No registries of patients with GSD are available. Information was included on living adult patients with GSD and patients who had died since 1967. Diagnosis of GSD had been confirmed by enzyme assay of each patient or of an affected sibling. Fifty-six physicians were individually contacted. Nineteen stated that they were not treating any adult patients with GSD. Thirteen physicians in private practice or at 1 of 12 medical centers filled out a detailed questionnaire or sent copies of clinic and hospital records that were reviewed by two of us. To obtain an estimate of how many patients might be missed by this survey, we reviewed records from a reference laboratory (Washington University) of 21 patients with GSD-Ia and of 21 patients with GSD-III who were diagnosed between 1955 and 1972. If still alive, these patients would now range in age from 18 to 64 years. Our study includes only 5 of these patients with GSD-I and 1 with GSD-III. Thus, this report incompletely represents North American patients with GSD who are currently older than 18 years of age. Clinical, radiographic, and laboratory findings at the latest visit were obtained, but data were not universally available for every item on the questionnaire. In analyzing each response, information was considered to be available only if specifically recorded; omission of information was not recorded as either a negative or a positive response. The presence of liver adenomas, nephrocalcinosis, or kidney stones was based on data from ultrasound or radiographic studies. The diagnosis of osteopenia was based on data from radiographic studies. The normal values for height were taken from the National Center for Health Statistics [12]. Normal values for serum chemistry tests [13] were used. Results Glycogen Storage Disease Type Ia Case Report Patient 1, a 43-year-old divorced father of one child, is a poultry farmer. A liver biopsy and enzymatic assay were obtained at 4 years of age because of poor growth, hypoglycemia without seizures, hepatomegaly, and frequent nosebleeds. Despite frequent meals, growth continued to be poor, puberty was delayed, and the final adult height of 168 cm was achieved after 20 years of age. Allopurinol was taken inconsistently after one of many gouty attacks beginning from 18 years of age. The patient did not complete high school. As an adult, he has smoked 2 to 4 packs of cigarettes per day. After divorcing in his 20s, he frequently skipped breakfast and failed to follow a recommended diet. Instead, his diet was high in fat and consisted primarily of foods that required little preparation, such as candy and sandwiches. He has always denied symptomatic hypoglycemia, although his serum glucose concentration after an overnight fast is about 2.8 mmol/L (50 mg/dL). Beginning in his mid-20s, he had recurrent episodes of flank pain and hematuria that were treated with antibiotics, and he passed kidney stones. At age 24, an intravenous pyelogram showed punctate calcificati


The Journal of Pediatrics | 1974

Autosomal dominant transmission of isolated growth hormone deficiency in iris-dental dysplasia (Rieger's syndrome)

Abdollah Sadeghi-Nejad; Boris Senior

A boy with Riegers syndrome was short and lacked GH. His father and sister, each of whom had Riegers syndrome, also had an isolated deficiency of GH. The paternal grandmother and a paternal uncle, in all likelihood, were similarly affected. Therapy with GH led to enhanced growth in the propositus. The GH-deficient subjects were sensitive to insulin and had a normal increase of insulin in response to arginine and to orally administered glucose. It is suggested that GH deficiency, in this family, is an inconstant component of Riegers syndrome and follows an autosomal dominant mode of transmission. A common embryologic developmental defect of the neural crest is postulated.


The New England Journal of Medicine | 1968

Studies of Liver Glycogenoses, with Particular Reference to the Metabolism of Intravenously Administered Glycerol

Boris Senior; Liliane Loridan

Abstract To investigate the pathophysiology of glycogenoses of the liver, glycerol, an endogenous precursor of glucose, was administered intravenously to eight patients and to 22 control subjects. ...


The Journal of Pediatrics | 1969

Cushing's syndrome in infancy.

Liliane Loridan; Boris Senior

Three infants and one 3-year-old child with Cushings syndrome are reported, and the published cases of Cushings syndrome in infancy are reviewed. One infant had a congenital form of Cushings syndrome, in another the disorder was associated with hemihypertrophy, and the 2 remaining patients had similar multiple congenital anomalies. Three of the patients had hyperplasia of the adrenal glands; the fourth had bilateral carcinoma. The clinical presentation of marked obesity, growth failure, and hypertension was uniform in the 4 patients. None was virilized. The urinary excretion of 17-hydroxycorticosteroids and the concentrations of cortisol in the plasma were increased. In the older patient the normal circadian pattern of adrenal secretion was absent, and the administration of dexamethasone failed to decrease the level of cortisol in the plasma.


The New England Journal of Medicine | 1990

Adrenomyeloneuropathy Presenting as Addison's Disease in Childhood

Abdollah Sadeghi-Nejad; Boris Senior

Adrenoleukodystrophy, a sex-linked peroxisomal disorder that results in the impaired oxidation of long-chain saturated fatty acids and causes neurologic impairment, is a rare cause of Addisons disease in children. Adrenomyeloneuropathy is the name given to a biochemically identical but milder and more slowly progressive variant of adrenoleukodystrophy that affects young adults, in whom adrenal insufficiency may long precede nervous system dysfunction. The transmission of adrenomyeloneuropathy, like that of most cases of adrenoleukodystrophy, is sex-linked. Because of a preponderance of male patients among a group of patients with the onset of adrenal failure in childhood, we questioned whether this condition might be the initial manifestation of adrenomyeloneuropathy. We therefore measured the plasma concentrations of very-long-chain saturated fatty acids in eight patients with adrenal insufficiency; of these, five had elevated plasma hexacosanoic acid concentrations (range, 2.42 to 6.43 mumol per liter; mean normal level [+/- SD], 0.83 +/- 0.45), confirming the presence of adrenomyeloneuropathy. Magnetic resonance imaging showed clear evidence of brain involvement in all five patients. Reexploration of the family histories revealed additional missed cases. We conclude that the possibility of adrenomyeloneuropathy should be considered in any boy with Addisons disease.


Metabolism-clinical and Experimental | 1983

Hypoketonemia and age-related fasting hypoglycemia in growth hormone deficiency

Joseph I. Wolfsdorf; Abdollah Sadeghi-Nejad; Boris Senior

Body fuels were measured in 45 normal children and 17 growth hormone-deficient patients after 24 hours of fasting. After three months of therapy with human Growth Hormone (hGH) 16 of the patients were restudied. In all groups, beta-hydroxybutyrate (BOHB) concentrations correlated inversely with age and with glucose concentrations. When adjusted for these factors, the concentrations of BOHB were significantly lower in the growth hormone-deficient patients than in the control children, before (P less than 0.01) as well as after therapy (P less than 0.01). Only the five youngest patients became hypoglycemic. During fasting, ketones, which serve as an alternative fuel for the brain, spare glucose. Thus, a shortage of ketones would compromise the ability of the patient to conserve glucose and predispose the patient to fasting hypoglycemia. Accordingly, we propose that hypoketonemia is a critical factor in the genesis of fasting hypoglycemia in growth hormone deficiency.


The Journal of Pediatrics | 1969

Gluconeogenesis and insulin in the ketotic variety of childhood hypoglycemia and in control children.

Boris Senior; Liliane Loridan

Following deprivation of carbohydrate and of calories, children with ketotic hypglycemia and control children exhibited equally low levels of glucose and of insulin. Gluconeogenesis from glycerol was unimpaired. In comparison with adults, children readily develop hypoglycemia when deprived of food, possibly due to the relatively greater mass of the brain and its greater need for fuel.


The New England Journal of Medicine | 1968

Functional differentiation of glycogenoses of the liver with respect to the use of glycerol.

Boris Senior; Liliane Loridan

Abstract In seven patients with glycogenoses of the liver the effects of glycerol administered by mouth on levels of glucose and of lactate, together with the response to epinephrine or glucagon, w...


The Journal of Pediatrics | 1971

Hypersecretion of insulin after the administration of l-leucine to obese children

Liliane Loridan; Abdollah Sadeghi-Nejad; Boris Senior

The administration of l -leucine by mouth to 8 markedly obese children resulted in elevations in the concentrations of insulin in the blood which were strikingly greater than those observed in control subjects. Such changes were not dependent on differences in the absolute doses of leucine. Despite the marked elevations of insulin after administration of leucine, the fall in concentrations of glucose differed little from that in the control subjects, reflecting a relative insensitivity to insulin in obese subjects. The increased secretion of insulin after administration of leucine to obese subjects correlates with an increased basal secretory capability of the islets and appears to be in keeping with a hyperresponsiveness of the islets of Langerhans to a variety of stimuli.


The Journal of Pediatrics | 1974

Studies in Type I glycogenosis of the liver: The genesis and disposition of lactate

Abdollah Sadeghi-Nejad; Esther Presente; Anna Binkiewicz; Boris Senior

Using a constant infusion of 14 C lactate, we have investigated the mechanism responsible for the increased concentration of lactate in four patients with Type I glycogenosis of the liver. The patients exhibited significantly increased rates of formation and disposal of lactate as well as increased incorporation of lactate into glucose. The results are interpreted as compatible with a dynamic pool of lactate generated by a recycling process between glycogen and lactate.

Collaboration


Dive into the Boris Senior's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Barbara Illingworth Brown

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Barry B. Bercu

University of South Florida

View shared research outputs
Researchain Logo
Decentralizing Knowledge